Sponsor Overview
Explore verified public information about Oncopeptides AB's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 2 supporting sources.
“Oncopeptides has established two programs to enable access to melphalan flufenamide (melflufen) for treatment of eligible patients with multiple myeloma who lack other treatment options, and where melflufen is not yet commercially available and are not to be provided through clinical trials.”
“Oncopeptides har etablerat två program för att ge lämpliga patienter med multipelt myelom tillgång till melfalan flufenamid (melflufen). Ett kriterium är att patienterna saknar andra behandlingsalternativ och inte kan få access till melflufen kommersiellt eller genom kliniska prövningar.”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 1 supporting sources.
Conditions: Relapsed and/or Refractory Multiple Myeloma
Reagan-Udall Foundation Insights
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.